Security Snapshot

Entrada Therapeutics, Inc. - Common Stock (TRDA) Institutional Ownership

CUSIP: 29384C108

13F Institutional Holders and Ownership History from Q4 2021 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

90

Shares (Excl. Options)

23.15MFull value: 23,148,846 · shares · 30 Sep 2026

Price

$6.35

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+251,240
Value change
-$370,422
Number of holders
90
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
39,243,586
SEC-reported price per share
$4.99
Insider filing price
$4.99
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • TRDA - Entrada Therapeutics, Inc. - Common Stock is tracked under CUSIP 29384C108.
  • 90 institutions reported positions in Q3 2026.
  • 7 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 127 to 90 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $214MFull value: $213,997,599 · USD · 30 Jun 2026
    to
    $146.98MFull value: $146,978,767 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 90 institutions filings for Q3 2026.

Open SEC evidence

Security key

29384C108

13F reference period

Q3 2026

13F holders

90

13D/G owners

7

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
7
Security
TRDA
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
5AM Ventures V, L.P. 11% $25,485,387 4,123,849 Kush Parmar 14 Nov 2025
MPM BioVentures 2014, L.P. 9.9% $28,205,935 3,885,115 ANSBERT GADICKE 08 Sep 2026
ROCHE FINANCE LTD 6.9% $23,019,270 2,569,115 Roche Finance Ltd 31 Dec 2024
BlackRock, Inc. 5.3% $17,691,090 1,974,452 BlackRock, Inc. 31 Dec 2024
JANUS HENDERSON GROUP PLC 4% -27% $9,964,391 -$3,932,443 1,521,281 -28% JANUS HENDERSON GROUP PLC 30 Jun 2025
TCG Crossover GP I, LLC 2.7% -46% $7,803,293 -$6,308,359 1,060,230 -45% TCG Crossover GP I, LLC 30 Jun 2026
PRICE T ROWE ASSOCIATES INC /MD/ 0.9% -84% $2,091,051 -$12,800,322 360,526 -86% T. Rowe Price Associates, Inc. 30 Sep 2025
As of 30 Sep 2026, 90 institutional investors reported holding
23.15MFull value: 23,148,846 · shares · 30 Sep 2026
shares of Entrada Therapeutics, Inc. - Common Stock (TRDA). This represents 59% of the company’s total
39.24MFull value: 39,243,586 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
52%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
BAKER BROS. ADVISORS LP 13% 5,072,730 0.15% $32,211,836
5AM Venture Management, LLC 9.6% 3,784,650 8.1% $24,032,528
Merck & Co., Inc. 4.4% 1,739,768 1.3% $11,047,527
Trails Edge Capital Partners, LP 3.6% 1,428,440 1.3% $9,070,594
VANGUARD CAPITAL MANAGEMENT LLC 3.2% 1,269,634 0% $8,062,176
TCG Crossover Management, LLC 2.7% 1,060,230 0.19% $6,732,461
WELLINGTON MANAGEMENT GROUP LLP 2.4% 954,419 0% $6,060,561
StepStone Group LP 1.9% 761,277 0.34% $4,834,109
GEODE CAPITAL MANAGEMENT, LLC 1.8% 708,490 0% $4,499,856
STATE STREET CORP 1.5% 589,101 0% $3,740,791
DIMENSIONAL FUND ADVISORS LP 0.88% 344,005 0% $2,184,119
GOLDMAN SACHS GROUP INC 0.76% 298,172 0% $1,893,394
Lynx1 Capital Management LP 0.71% 278,606 0.27% $1,769,148
J. Goldman & Co LP 0.68% 268,081 0.06% $1,702,314
GSA CAPITAL PARTNERS LLP 0.67% 262,682 0.1% $1,668,000
VANGUARD PORTFOLIO MANAGEMENT LLC 0.67% 261,475 0% $1,660,366
Longaeva Partners L.P. 0.58% 226,520 0.04% $1,438,402
RENAISSANCE TECHNOLOGIES LLC 0.51% 199,200 0% $1,264,920
VANGUARD FIDUCIARY TRUST CO 0.46% 179,872 0% $1,142,187
Quantinno Capital Management LP 0.42% 165,752 0% $1,052,525
BANK OF AMERICA CORP /DE/ 0.38% 150,489 0% $955,605
Qube Research & Technologies Ltd 0.38% 150,225 0% $953,929
Woodline Partners LP 0.37% 145,600 0% $924,560
Trexquant Investment LP 0.36% 139,918 0.01% $888,479
TWO SIGMA INVESTMENTS, LP 0.28% 111,489 0% $707,955

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
20
Headline period
Q3 2026
Rows shown
1-20 of 20
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 23,148,846 $146,978,767 -$370,422 $6.35 90
2026 Q2 29,052,007 $213,997,599 +$23,782,839 $7.36 127
2026 Q1 25,477,255 $321,439,067 +$9,380,200 $12.62 118
2025 Q4 24,428,116 $250,955,377 +$6,143,063 $10.28 113
2025 Q3 28,408,651 $164,766,270 -$9,410,304 $5.80 114
2025 Q2 29,583,750 $198,790,015 -$4,881,409 $6.72 105
2025 Q1 30,241,830 $274,509,238 -$4,478,805 $9.04 110
2024 Q4 30,637,008 $529,755,566 +$9,629,460 $17.29 102
2024 Q3 30,099,996 $481,057,545 +$6,089,620 $15.98 97
2024 Q2 29,668,185 $422,803,373 +$52,052,901 $14.25 82
2024 Q1 26,027,444 $368,797,900 -$3,772,264 $14.17 76
2023 Q4 26,281,861 $396,641,035 +$3,492,844 $15.09 62
2023 Q3 26,035,608 $411,375,608 +$4,515,692 $15.80 55
2023 Q2 25,751,810 $389,877,766 +$13,317,282 $15.14 56
2023 Q1 24,900,040 $361,043,649 +$2,708,627 $14.50 53
2022 Q4 24,715,588 $334,178,958 +$2,434,963 $13.52 46
2022 Q3 24,517,008 $386,369,092 -$2,728,204 $15.76 33
2022 Q2 24,778,477 $301,833,417 -$12,927,920 $12.18 35
2022 Q1 25,876,494 $242,821,140 +$2,263,033 $9.39 48
2021 Q4 24,861,440 $425,110,000 +$413,748,000 $17.12 45
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .